Anti human cd16 clone 3g8

Wheeler M.M., Stilp A.M., Rao S., Halldórsson B.V., Beyter D., Wen J., Mihkaylova A.V., McHugh C.P., Lane J., Jiang M.Z., Raffield L.M., Jun G., Sedlazeck F.J., Metcalf G., Yao Y., Bis J.B., Chami N., de Vries P.S., Desai P., Floyd J.S., Gao Y., Kammers K., Kim W., Moon J.Y., Ratan A., Yanek L.R., Almasy L., Becker L.C., Blangero J., Cho M.H., Curran J.E., Fornage M., Kaplan R.C., Lewis J.P., Loos R.J., Mitchell B.D., Morrison A.C., Preuss M., Psaty B.M., Rich S.S., Rotter J.I., Tang H., Tracy R.P., Boerwinkle E., Abecasis G.R., Blackwell T.W., Smith A.V., Johnson A.D., Mathias R.A., Nickerson D.A., Conomos M.P., Li Y., Þorsteinsdóttir U., Magnússon M.K., Stefansson K., Pankratz N.D., Bauer D.E., Auer P.L, & Reiner A.P. (2022). Whole genome sequencing identifies structural variants contributing to hematologic traits in the NHLBI TOPMed program. Nature Communications, 13, 7592.

Rataj F., Jacobi S.J., Stoiber S., Asang F., Ogonek J., Tokarew N., Cadilha B.L., van Puijenbroek E., Heise C., Duewell P., Endres S., Klein C, & Kobold S. (2018). High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. British Journal of Cancer, 120(1), 79-87.